Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

Chemotherapy-induced Febrile Neutropenia Clinical Trial

Official title:
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

Status Completed

Clinical Trial Summary

To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02178475
Study type	Observational
Source	Amgen
Contact
Status	Completed
Phase
Start date	July 18, 2014
Completion date	October 28, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02467868` - Efficacy and Safety Study With MYL-1401H and Neulasta	Phase 3
Completed	`NCT04000711` - Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia	N/A
Recruiting	`NCT03823950` - Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients	Phase 4
Completed	`NCT01813721` - Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.	N/A